Beam TherapeuticsMEX:BEAM 66 Return-on-Tangible-Equity is -31.43% as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN519.96 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,199 Biotechnology companies, Beam Therapeutics ranks better than 73.31% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Beam Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was MXN-6,803 Mil. Beam Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN21,648 Mil. Therefore, Beam Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -31.43%.
The historical rank and industry rank for Beam Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
MEX:BEAM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -177.53 Med: -55.31 Max: -5.87
Current: -5.87
During the past 9 years, Beam Therapeutics's highest Return-on-Tangible-Equity was -5.87%. The lowest was -177.53%. And the median was -55.31%.
MEX:BEAM's Return-on-Tangible-Equity is ranked better than 73.31% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs MEX:BEAM: -5.87
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Beam Therapeutics Return-on-Tangible-Equity Related Terms
Beam Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BEAM vs ELVN, IDYA, PBLS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Beam Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -31.43% mean?
Beam Therapeutics (MEX:BEAM) has a Return-on-Tangible-Equity of -31.43% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #320 out of 1199 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Beam Therapeutics' Return-on-Tangible-Equity too high?
Beam Therapeutics' current Return-on-Tangible-Equity is -31.43%. Based on the distribution chart, Beam Therapeutics ranks #320 out of 1199 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Return-on-Tangible-Equity compare to ELVN and IDYA?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #320 out of 1199 companies for Return-on-Tangible-Equity. This puts Beam Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Return-on-Tangible-Equity is -31.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN519.96, compared to a current price of MXN628.46 — trading 20.9% above its estimated fair value. The current Return-on-Tangible-Equity is -31.43%. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Return-on-Tangible-Equity is -31.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 20.9% above its estimated GF Value™ of MXN519.96.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
Return-on-Tangible-Equity: -31.43%
GF Value™: MXN519.96 vs. price of MXN628.46 (20.9% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score
Get the complete analysis for MEX:BEAM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
